Chongqing Fortune Pharmaceutical Co., Ltd. Report issue

Government Phase 1 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01736891
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Fortune Pharmacal Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

rasagiline (azilect) (1 trial)

Drugs in Phase 1 Trials (1)

acetaminophen (tylenol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Parkinson Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2